Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0025202 (
melanoma
)
69,561
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Genistein, an in vitro inhibitor of topoisomerase II and
tyrosine
kinases, elicited an inhibition of growth and increased melanin content in five human
melanoma
cell lines, after six days of treatment at a concentration of 45 microM. In two lines examined more thoroughly, HO and SK-MEL-131, treatment with genistein also increased other markers of differentiation, including tyrosinase activity, reactivity with CF21 monoclonal antibody, and dendrite-like structure formation. The genistein-evoked increases in melanin content and tyrosinase activity were concentration- and time-dependent. Treatment of HO and SK-MEL-131 cells with 45 microM genistein for 24 hr or 60-600 microM genistein for only 1 hr resulted in an increase in protein-linked DNA strand breaks. Our results suggest an association between the genistein-evoked, protein-linked, DNA strand breaks and the genistein-induced differentiation of human
melanoma
cells.
...
PMID:Genistein-induced cell differentiation and protein-linked DNA strand breakage in human melanoma cells. 211 63
Phenolic melanin precursors can be utilized for the development of anti-
melanoma
agents. The sulphur homologue of
tyrosine
, 4-S-cysteinylphenol (CP) and its decarboxylation product, 4-S-cysteaminylphenol (CAP) were shown to be substrates of
melanoma
tyrosinase, forming melanin-like pigment. Both, but in particular the 4-S-CAP, exhibited a significant in vivo depigmenting effect. Here, we report on the in vivo anti-
melanoma
effect of 4-S-CP, and 4-S-CAP and its N-acetyl derivative. In a previous in vitro study, it was shown that 4-S-CP and 4-S-CAP required a catalytic amount of dopa for optimal mammalian tyrosinase activity. To enhance the potential anti-
melanoma
effect of these two compounds. L-dopa and a decarboxylase inhibitor (carbidopa) were given concomitantly. We found that 4-S-CAP showed a significant growth inhibition of B16
melanoma
inoculated s.c. into C57BL/6J mice. The anti-
melanoma
effect was increased significantly by combination of L-dopa and carbidopa. In addition, we tested the in vivo anti-
melanoma
effect of an N-acetyl derivative of 4-S-CAP (N-Ac-4-S-CAP). We found that N-Ac-4-S-CAP was the tyrosinase substrate and potent inhibitor of
melanoma
growth. N-acetyl 4-S-CAP showed a marked increase in water solubility. We suggest that N-Ac-4-S-CAP may prove to be a valuable model for the development of anti-
melanoma
agent using a metabolic pathway of melanin synthesis.
...
PMID:The in vivo antimelanoma effect of 4-S-cysteaminylphenol and its n-acetyl derivative. 212 52
2-Thiouracil (TU), an antithyroid drug, is receiving growing interest as a specific tumor marker for
malignant melanoma
, owing to its capability of being selectively accumulated into active melanin-producing tissues. However, up until now, the molecular mechanism of TU uptake by growing melanin has remained largely unknown. In an attempt to fill this gap, we have investigated the effect of TU on the tyrosinase catalyzed oxidation of
tyrosine
. At a concentration of 0.5 mM, TU was found to totally inhibit melanin formation by tyrosinase catalyzed oxidation of 0.25 mM
tyrosine
in phosphate buffer at pH 6.8. Polarographical monitoring of oxygen consumption under conditions of complete suppression of melanogenesis revealed a significant tyrosinase activity, with TU acting as a modest non-competitive inhibitor of the enzyme (Ki = 0.6 mM). HPLC and TLC analysis of the
tyrosine
-tyrosinase reaction in the presence of excess TU showed that the substrate is progressively consumed and a major hitherto unknown product (lambda max = 284 nm), positive to ninhydrin and ferric chloride, is concomitantly formed. This was isolated by repeated gel filtration chromatography of the reaction mixture on Sephadex G-10 and was formulated as the TU-dopa adduct 3,4-dihydroxy-6-(4'-hydroxypyrimidinyl-2'-thio)phenylalanine by spectral analysis. These results suggest that selective TU incorporation in pigmented melanomas and other melanin-producing systems is due to the covalent binding to dopaquinone, produced by tyrosinase catalyzed oxidation of
tyrosine
.
...
PMID:Selective uptake of 2-thiouracil into melanin-producing systems depends on chemical binding to enzymically generated dopaquinone. 212 40
Phosphonic acid and phosphinic acid analogues of
tyrosine
and 3,4-dihydroxyphenylalanine (dopa) were found to influence tyrosinase activity, thus being potential regulators of melanization in mammalian cells. The analogues were tested for their cytostatic activity in vitro, by means of total cell protein determination, on mouse B16
melanoma
and, for comparison, on human KB carcinoma cell lines. Four compounds out of 22 revealed promising cytostatic activity for both cell lines, being nearly equipotent with dopa. Those compounds which most effectively suppressed the growth of both tumour cell lines were the same as those which had a significant influence on tyrosinase activity regardless of whether they acted as inhibitors or substrates.
...
PMID:Phosphonic and phosphinic acid analogues of tyrosine and 3,4-dihydroxyphenylalanine (dopa) as potential antimelanotic agents. 212 80
Tumor cells may stimulate their own proliferation through an autocrine mechanism by simultaneously producing growth factors and growth factor receptors. We now report that numerous human tumor-derived cell lines simultaneously express the genes for platelet-derived growth factor (PDGF) A and B chains and the PDGF receptor (PDGF-R). Measurement of mRNA transcribed from these genes showed that among 16 malignant glioma cell lines tested, 15 expressed the PDGF A gene, 12 expressed the PDGF B gene, and 13 expressed the PDGF-R gene. Of three osteosarcoma lines, three expressed PDGF A, two expressed PDGF B, and three expressed PDGF-R. For eight
malignant melanoma
lines, seven expressed PDGF A, five expressed PDGF B, and three expressed PDGF-R genes. Thus, 13 of 16 malignant glioma, 3 of 3 osteosarcomas, and 3 of 8
malignant melanoma
cell lines expressed the PDGF receptor gene and either or both PDGF genes. Five cell lines were tested for production of biologically active PDGF and PDGF receptor protein. Media conditioned by each of the five cell lines induced
tyrosine
phosphorylation of a protein identical in size to the PDGF receptor. These five cell lines also produced PDGF receptor protein as measured by Western blot analysis or metabolic labeling and immunoprecipitation using PDGF-R antibodies. The PDGF receptors of these cell lines were activated by human platelet PDGF or by recombinant AA or BB homodimers. Intracellular interaction of these receptors with the growth factor simultaneously produced may provide continuous stimulation to the proliferation of these cells.
...
PMID:Platelet derived growth factor (PDGF) autocrine components in human tumor cell lines. 215 59
In order to segregate multiple activities ascribed to IL-1, various human IL-1 alpha derivatives were produced by recombinant DNA technology. A derivative substituted at the 151st Asp with
Tyr
(termed to be TN-55) showed unique characteristics. TN-55 lost the PGE2 inducing activity in a human osteosarcoma cell line (MG-63) and growth promoting activity for a human dermal fibroblast cell line (CCD-27Sk), but partially remained LAF activity in mouse thymocyte, cytostatic activity against a human
melanoma
cell line (A-375) and IL-2 inducing activity in a human T cell line (HSB.2). Although TN-55 bound to the receptor on MG-63 cells with a similar affinity as native IL-1 alpha, TN-55 not only failed in inducing PGE2 production but also antagonized the PGE2 inducing action of IL-1 alpha or IL-1 beta. Thus, TN-55 seems to work as a receptor antagonist. Moreover, TN-55 did not stimulate ACTH secretion in rats in vivo. On the other hand, TN-55 induced PGE2 production in a rabbit dermal fibroblast cell line (RAB-9) and exhibited pyrogenicity in rabbits in vivo. These data suggest that TN-55 has different species-cross reactivity from native IL-1 alpha. In conclusion, multiple biological activities of IL-1 alpha can be segregated by substituting one amino acid. TN-55 may be an ideal IL-1 agonist which lacks inflammatory characteristics of IL-1 (e.g. PGE2-dependent activities) in human but partially retained T lymphocyte stimulating activity and tumor cytostatic activity. In addition, TN-55 may also work as an IL-1 antagonist to block PGE2 production induced by IL-1 through receptor competition.
...
PMID:A human IL-1 alpha derivative which lacks prostaglandin E2 inducing activity and inhibits the activity of IL-1 through receptor competition. 216 12
Amino acid restriction modulates tumor growth, although effects on metastasis are poorly documented. We demonstrate that low levels of
tyrosine
(
Tyr
) and phenylalanine (Phe) suppress metastasis of B16-BL6
melanoma
and that these effects are specific to these two amino acids. Weight loss and sustained low body weight in mice fed low
Tyr
and Phe diet do not contribute to the antimetastatic effects. Furthermore, methionine (Met) restriction, which decreased survival of mice inoculated i.p. with B16
melanoma
, only slightly inhibited spontaneous metastasis compared to the dramatic inhibition during
Tyr
and Phe restriction.
Tyr
and Phe restriction inhibited spontaneous metastasis by impairing the ability of tumor cells to establish metastatic foci and not via differential tumor cell removal from the blood. Spontaneous metastasis is blocked by
Tyr
and Phe intervention even in mice with established lymph node tumors. Tumors isolated from mice fed low
Tyr
and Phe diet reinoculated into mice fed normal diet exhibited lower experimental metastatic potential, reflected by decreased formation of lung tumor colonies and increased survival of inoculated mice. This decrease in metastatic potential is not associated with tumor chemosensitivity. These findings indicate that
Tyr
and Phe restriction could become an important adjuvant to effective
melanoma
treatment.
...
PMID:Specificity of the suppression of metastatic phenotype by tyrosine and phenylalanine restriction. 220 33
We previously demonstrated that
tyrosine
(
Tyr
) and phenylalanine (Phe) restriction suppresses metastatic heterogeneity of B16-BL6 (BL6)
melanoma
and selects for tumor variants with decreased metastatic potential. In this study, we investigate stability of this
Tyr
- and Phe-modulated tumor phenotype by sequentially transplanting BL6 in vivo into mice fed Low
Tyr
and Phe Diet. Metastatic potential of BL6 is suppressed after one subcutaneous passage. Suppression is unlikely to result from inhibition of tumor growth, since growth in vitro is significantly increased. The metastatic potential of the
Tyr
- and Phe-modulated tumor is unstable after in vivo passage, and lung colonizing ability is regenerated after ten in vivo passages. Conversely, the antimetastatic effect of
Tyr
and Phe restriction is stable after prolonged in vitro passage. The metastatic potential of tumors from mice fed Normal Diet is unstable after long-term in vitro culture. Sensitivity to adriamycin of BL6 from mice fed Low
Tyr
and Phe Diet is increased and is not altered by change in metastatic potential.
...
PMID:Phenotypic stability of B16-BL6 melanoma exposed to low levels of tyrosine and phenylalanine. 224 Nov 8
The melanin precursor analogue p-boronophenylalanine (BPA) has been used to deliver 10B to
melanoma
tissue for boron neuron capture therapy. Uptake studies in tumor models other than
melanoma
now indicate that BPA is capable of delivering therapeutic amounts of boron to tumors other than
melanoma
. The KHJJ murine mammary tumor carried s.c. in BALB/c mice, the GS-9L rat glioma carried both s.c. and intracranially in F-344 rats, and the human U-87 MG glioma xenograft carried s.c. in nude mice have all shown significant accumulation of boron in tumor tissue following single p.o. (intragastric) doses of BPA. In this KHJJ mammary tumor, the L isomer of BPA was preferentially accumulated compared to the D isomer, indicative of a carrier-mediated transport process. Double-label, whole-body autoradiographic studies in a pigmented murine
melanoma
have shown that the boron distribution (from BPA) differs from the distribution of a tritiated melanin precursor (
tyrosine
). Boron accumulated only in the tumor; labeled
tyrosine
accumulated in tumor, liver, intestinal epithelium, bone-marrow, and secretory glands. Toxicity studies in mice and rabbits indicate that, even at very high doses, BPA p.o. caused no adverse effect in tissues, on blood chemistry, or on differential leukocyte counts. These data indicate that BPA may be generally useful as a boron delivery agent for boron neutron capture therapy of tumors.
...
PMID:Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. 229 47
The potential use of 4-hydroxyanisole as a chemotherapeutic agent in the treatment of
malignant melanoma
led us to investigate the kinetics of oxidation of this
tyrosine
analogue by tyrosinase. We found that addition of amino acids accelerated the reaction, resulting in a reduction in length of the characteristic lag period of monohydric phenol oxidation. The lag period was abolished completely by an aliquot of exhausted 4-hydroxyanisole/tyrosinase reaction mixture and by very low concentrations of thiol-containing compounds. We conclude that the reaction-accelerating property of non-thiol amino acids is due to the reductive addition of the ortho-quinone reaction product to nucleophilic groups of the amino acids. The dihydric phenol product which results is capable of met-tyrosinase recruitment by electron donation to the cupric active site generating the cuprous form of the enzyme which binds oxygen and is able to oxidise monohydric phenols. Abolition of the lag period by an aliquot of exhausted reaction mixture is probably due to recruitment of the met-enzyme by catecholic oligomers of the quinone product. Thiol containing compounds are able to abolish the lag period due to the ability of these compounds to reduce met-tyrosinase directly.
...
PMID:Studies on the kinetics of oxidation of 4-hydroxyanisole by tyrosinase. 249 99
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>